These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 15959405)

  • 1. [Coming clinical recommendations: where will the glitazones fit in?].
    Halimi S
    Ann Endocrinol (Paris); 2005 Apr; 66(2 Pt 2):1S59-70. PubMed ID: 15959405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Glitazones clinical data: an update].
    Guerci B
    Ann Endocrinol (Paris); 2005 Apr; 66(2 Pt 2):1S45-58. PubMed ID: 15959404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment recommendations for type 2 diabetes. Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS)].
    Diabetes Metab; 1999 Dec; 25 Suppl 6():1-79. PubMed ID: 10697746
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting insulin resistance and beta-cell dysfunction: the role of thiazolidinediones.
    Del Prato S; Marchetti P
    Diabetes Technol Ther; 2004 Oct; 6(5):719-31. PubMed ID: 15628822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
    Mudaliar S; Henry RR
    Annu Rev Med; 2001; 52():239-57. PubMed ID: 11160777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
    Massi-Benedetti M; Orsini-Federici M
    Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durability of glycemic control: a feature of the thiazolidinediones.
    Serdy S; Abrahamson MJ
    Diabetes Technol Ther; 2004 Apr; 6(2):179-89. PubMed ID: 15117584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel pharmacologic agents for type 2 diabetes.
    Uwaifo GI; Ratner RE
    Endocrinol Metab Clin North Am; 2005 Mar; 34(1):155-97. PubMed ID: 15752927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone and sulfonylureas: effectively treating type 2 diabetes.
    Hanefeld M
    Int J Clin Pract Suppl; 2007 Jun; 61(153):20-7. PubMed ID: 17594390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.
    Vora J; Caputo S; Damci T; Orozco-Beltran D; Pan C; Svendsen AL; Sølje KS; Khunti K;
    J Clin Pharm Ther; 2014 Apr; 39(2):136-43. PubMed ID: 24329524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnostic and therapeutic management of common lumbago and sciatica of less than 3 months of duration. Recommendations of the ANAES. Agence Nationale d'Accréditation et d'Evaluation en Santé].
    J Radiol; 2000 Nov; 81(11):1665-6. PubMed ID: 11104986
    [No Abstract]   [Full Text] [Related]  

  • 12. Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents.
    Dandona P; Aljada A
    J Diabetes Complications; 2004; 18(2):91-102. PubMed ID: 15120703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. beta-cell function and anti-diabetic pharmacotherapy.
    Del Prato S; Bianchi C; Marchetti P
    Diabetes Metab Res Rev; 2007 Oct; 23(7):518-27. PubMed ID: 17883249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiology and pharmacological treatment of insulin resistance.
    Matthaei S; Stumvoll M; Kellerer M; Häring HU
    Endocr Rev; 2000 Dec; 21(6):585-618. PubMed ID: 11133066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Glitazones more than hypoglycemics in type 2 diabetes].
    Sjöholm A
    Lakartidningen; 2007 Oct 24-30; 104(43):3201-3. PubMed ID: 18018938
    [No Abstract]   [Full Text] [Related]  

  • 16. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
    Viberti G
    J Diabetes Complications; 2005; 19(3):168-77. PubMed ID: 15866064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of type 2 diabetes mellitus. Role of thiazolidinediones.
    Noble J; Baerlocher MO; Silverberg J
    Can Fam Physician; 2005 May; 51(5):683-7. PubMed ID: 15934272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E; Schnell O
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract]   [Full Text] [Related]  

  • 19. [Glitazones critically evaluated].
    Schernthaner G
    Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
    [No Abstract]   [Full Text] [Related]  

  • 20. New directions in type 2 diabetes mellitus: an update of current oral antidiabetic therapy.
    Brown DL; Brillon D
    J Natl Med Assoc; 1999 Jul; 91(7):389-95. PubMed ID: 10643211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.